ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • computed tomography (CT) and rheumatoid arthritis (RA)
  • computed tomography (CT) and spine involvement
  • computed tomography (CT) and spondylarthritis
  • Computed tomography (CT) and vasculitis
  • computed tomography (CT) and x-ray
  • Conduction system
  • Confocal Microscopy
  • Confounding
  • Congenital Heart Block
  • Connective Tissue Disease
  • Connective tissue diseases
  • connective tissue diseases and biomarkers
  • connective tissue diseases and computed tomography (CT)
  • connective tissue diseases and diagnosis
  • connective tissue diseases and glucocorticoids
  • connective tissue diseases and hepatic disorders
  • connective tissue diseases and hydroxychloroquine
  • connective tissue diseases and interferons
  • Connective tissue diseases and interstitial lung disease
  • connective tissue diseases and laboratory tests
  • connective tissue diseases and nailfold capillaroscopy
  • Connective tissue diseases and outcome measures
  • connective tissue diseases and prognostic factors
  • Connective tissue diseases and pulmonary complications
  • connective tissue diseases and Raynaud's phenomenon
  • Connective tissue diseases and rheumatoid arthritis (RA)
  • Connective tissue diseases and sarcoidosis
  • connective tissue diseases and systemic lupus erythematosus (SLE)
  • connective tissue diseases and systemic sclerosis
  • connective tissue diseases and systemic vasculitides
  • connective tissue diseases and vasculitis
  • Connective tissue disorder
  • consult
  • consults
  • consults and education
  • consults and educational research
  • consults and gout
  • consults and health care cost
  • consults and patient-reported outcome measures
  • contraception
  • contraception and teratogenic medications
  • Contraceptive Methods
  • Contractures
  • conversation and interdisciplinary rheumatology team
  • COPA syndrome
  • Copd
  • copd and dual energy x-ray absorptiometry (DEXA)
  • Copd and osteoporosis
  • copd and vasculitis
  • coping
  • Coping skills
  • Coping skills and fibromyalgia
  • Copy number variations
  • CorEvitas
  • Coronary Aneurysm
  • Coronary Aneurysm and corticosteroids
  • Coronary Aneurysm and Kawasaki disease
  • Coronary Aneurysm and Retroperitoneal Fibrosing
  • coronary artery aneurisms
  • coronary artery disease
  • Coronary artery disease (CAD)
  • coronary artery disease and atherosclerosis
  • coronary artery disease and gout
  • coronary artery disease and lupus nephritis
  • coronary artery disease and osteoprotegerin
  • coronary artery disease and psoriatic arthritis
  • coronary artery disease and rheumatoid arthritis
  • coronary artery disease and rheumatoid arthritis (RA)
  • coronary artery disease and systemic lupus erythematosus (SLE)
  • coronary atherosclerosis
  • coronary atherosclerosis progression
  • coronary plaque
  • corticosteroids
  • corticosteroids and atherosclerosis
  • corticosteroids and bone density
  • corticosteroids and cancer treatments
  • corticosteroids and cardiovascular disease
  • corticosteroids and Early Rheumatoid Arthritis
  • corticosteroids and fractures
  • Corticosteroids and giant cell arteritis
  • corticosteroids and glomerulonephritis
  • corticosteroids and glucocorticoids
  • corticosteroids and gout
  • corticosteroids and hip disorders
  • corticosteroids and immunosuppressants
  • Corticosteroids and infection
  • corticosteroids and interferons
  • corticosteroids and intima medial thickness
  • corticosteroids and juvenile dermatomyositis
  • corticosteroids and Lupus
  • corticosteroids and meta-analysis
  • corticosteroids and osteoarthritis
  • corticosteroids and osteonecrosis
  • Corticosteroids and pain
  • Corticosteroids and rheumatoid arthritis
  • corticosteroids and rheumatoid arthritis (RA)
  • corticosteroids and rituximab
  • Corticosteroids and systemic lupus erythematosus (SLE)
  • corticosteroids and treatment
  • corticosteroids and treatment options
  • corticosteroids and uveitis
  • corticosteroids and vasculitis
  • cost
  • cost and morbidity and mortality
  • cost and myositis
  • Cost containment
  • Cost containment and etanercept
  • cost containment and health care cost
  • cost containment and high risk
  • cost containment and inflammatory arthritis
  • cost containment and infliximab
  • cost containment and laboratory tests
  • cost containment and primary care
  • cost containment and psoriatic arthritis
  • cost containment and remission
  • cost containment and rheumatic disease
  • cost containment and rheumatoid arthritis (RA)
  • Cost containment and systemic lupus erythematosus (SLE)
  • cost containment and trainee
  • cost containment and vasculitis
  • Cost-Effectiveness
  • costs
  • Costs of Healthcare utilization
  • Counseling
  • Counseling and osteoarthritis
  • Counseling and women's health
  • COVID-19
  • COX inhibitors
  • COX-2
  • CPPD
  • Creatinine kinase
  • creatinine kinase and prognostic factors
  • Critical care
  • CRMO
  • CRMO and canakinumab
  • Crohn's Disease
  • cross-sectional studies
  • cross-sectional studies and patient outcomes
  • Crossover Study
  • Cryofibrinogen
  • Cryofibrinogenemia
  • Cryogloblulinemic Vasculitis
  • Cryoglobulinemia
  • cryoglobulinemia and parvovirus B19
  • cryoglobulinemia and rheumatoid arthritis (RA)
  • Cryoglobulinemia and vasculitis
  • Cryoglobulinemic Vasculitis
  • Crystal-induced arthritis
  • crystal-induced arthritis and degenerative arthritis
  • Crystal-induced arthritis and genetics
  • crystal-induced arthritis and gout
  • crystal-induced arthritis and health outcome
  • crystal-induced arthritis and hyperuricemia
  • crystal-induced arthritis and inflammasome activation
  • crystal-induced arthritis and medication
  • crystal-induced arthritis and osteoarthritis
  • crystal-induced arthritis and prednisolone
  • crystal-induced arthritis and quality improvement
  • crystal-induced arthritis and shoulder disorders
  • Crystal-induced arthritis and synovial fluid
  • crystal-induced arthritis and ultrasound
  • CSA
  • csDMARDs
  • cSLE (childhood-onset systemic lupus erythematosus
  • css
  • CT-P13 and ankylosing spondylitis (AS)
  • CTD and corticosteroids
  • CTLA-4
  • CTLA-4 and abatacept
  • CTLA-4 and IDO1
  • CTLA4
  • CTLA4-Ig
  • cumulative
  • curcuma longa
  • Curriculum
  • Curriculum and education
  • Curriculum and pediatric rheumatology
  • Curriculum and systemic lupus erythematosus (SLE)
  • Curriculum and ultrasound
  • Cutaneous
  • cutaneous lupus
  • cutaneous lupus and innate immunity
  • cutaneous lupus and nephritis
  • Cutaneous lupus erythematosus
  • cutaneous lupus erythematosus and Autoimmune Skin Disease
  • cutaneous lupus erythematosus and cutaneous manifestations
  • Cutaneous lupus erythematosus and dermatomyositis
  • cutaneous lupus erythematosus and interferons
  • cutaneous lupus erythematosus and population studies
  • cutaneous lupus erythematosus and race/ethnicity
  • cutaneous lupus erythematosus and single cell RNAseq
  • cutaneous lupus erythematosus and systemic lupus erythematosus (SLE)
  • Cutaneous manifestations
  • cutaneous manifestations and dermatomyositis
  • cutaneous manifestations and environmental factors
  • cutaneous manifestations and juvenile SLE
  • cutaneous manifestations and lpr
  • cutaneous manifestations and patient outcomes
  • Cutaneous manifestations and polyarteritis nodosa
  • cutaneous manifestations and security
  • First |
  • « Previous Page
  • 10
  • 11
  • 12
  • 13
  • 14
  • [15]
  • 16
  • 17
  • 18
  • 19
  • 20
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology